RHYTHM PHARMCTL (NASDAQ:RYTM) major shareholder S.A. Ipsen bought 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $340,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
RHYTHM PHARMCTL Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for RHYTHM PHARMCTL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RHYTHM PHARMCTL and related companies with MarketBeat.com's FREE daily email newsletter.